Taysha Gene Therapies, Inc.

TSHA

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001806310

SEC filings (opens in a new tab)

In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Taysha Gene Therapies, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025 All holders in Q1 2025

13F holders of TSHA: Q1 2025 compared with Q2 2025
Measure	Q1 2025	Of which not filed for Q2 2025	Q2 2025	Change
Holders	127	1	150	+24
Shares	166.9M	435	257.7M	+90.9M (+54.5%)
Value	$232.0M	$605	$595.4M	+$363.4M (+156.7%)

1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (44)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to TSHA in Q2 2025
Institution	Shares	Value	% of portfolio
Deerfield Management Company, L.P. (Series C)	5,386,000	$12.4M	0.23%
Adage Capital Partners GP, L.L.C.	4,839,000	$11.2M	0.02%
Toronto Dominion Bank	4,728,806	$10.9M	0.02%
Suvretta Capital Management, LLC	3,217,449	$7.43M	0.28%
Vestal Point Capital, LP	3,000,000	$6.93M	0.36%
MPM Oncology Impact Management LP	2,953,562	$6.82M	1.18%
Great Point Partners LLC	1,500,000	$3.46M	2.25%
StemPoint Capital LP	1,203,941	$2.78M	0.90%
Tang Capital Management LLC	900,000	$2.08M	0.11%
Anson Funds Management LP	803,500	$1.86M	0.34%
SG Americas Securities, LLC	493,301	$1.14M	0.01%
Acuta Capital Partners, LLC	485,669	$1.12M	1.57%
Sphera Funds Management Ltd.	420,000	$970.2K	0.25%
D. E. Shaw & Co., Inc.	401,509	$927.5K	0.00%
Affinity Asset Advisors, LLC	200,000	$462.0K	0.07%
Quadrature Capital Ltd	161,940	$373.3K	0.01%
ExodusPoint Capital Management, LP	148,357	$343.0K	0.00%
Jane Street Group, LLC	136,994	$316.5K	0.00%
Rafferty Asset Management, LLC	118,683	$274.2K	0.00%
Squarepoint Ops LLC	100,226	$231.5K	0.00%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.	80,571	$186.1K	0.00%
Marshall Wace, LLP	79,498	$183.6K	0.00%
Omers Administration Corp	72,900	$168.4K	0.00%
Militia Capital Partners, LP	66,800	$154.3K	0.07%
Engineers Gate Manager LP	64,617	$149.3K	0.00%
Axq Capital, LP	57,000	$131.7K	0.04%
Renaissance Technologies LLC	54,900	$126.8K	0.00%
Gsa Capital Partners LLP	44,690	$103.0K	0.01%
Two Sigma Investments, LP	32,682	$75.5K	0.00%
Ethic Inc.	27,975	$66.6K	0.00%
Profund Advisors LLC	26,599	$61.4K	0.00%
Point72 Asia (Singapore) Pte. Ltd.	25,252	$58.3K	0.01%
May Hill Capital, LLC	16,051	$37.1K	0.01%
E Fund Management Co., Ltd.	13,214	$30.5K	0.00%
Ieq Capital, LLC	10,063	$23.2K	0.00%
St Germain D J Co Inc	5,300	$12.2K	0.00%
Raymond James Financial Inc	3,605	$8.33K	0.00%
Headlands Technologies LLC	3,037	$7.01K	0.00%
Simplex Trading, LLC	3,263	$7.00K	0.00%
Clearstead Advisors, LLC	690	$1.59K	0.00%
Essential Partners LLC	327	$755	0.00%
Rothschild Investment LLC	105	$243	0.00%
National Bank of Canada	48	$110	0.00%
IFP Advisors, Inc	14	$32	0.00%

Sold out (20)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.

Institutions that sold out of TSHA in Q2 2025
Institution	Shares, Q1 2025	Value, Q1 2025
Superstring Capital Management LP	755,599	$1.05M
DAFNA Capital Management LLC	522,500	$726.3K
HRT Financial LP	139,692	$194.0K
BIT Capital GmbH	117,062	$162.7K
Corebridge Financial, Inc.	85,878	$119.4K
Y-Intercept (Hong Kong) Ltd	83,864	$116.6K
Mariner, LLC	58,490	$81.3K
Jain Global LLC	45,200	$62.8K
Ameriprise Financial Inc	22,844	$31.8K
HSBC Holdings PLC	20,257	$27.7K
Two Sigma Securities, LLC	13,071	$18.2K
SIH Partners, LLLP	12,173	$16.9K
Catalyst Funds Management Pty Ltd	11,900	$16.5K
Camelot Portfolios, LLC	11,000	$15.3K
CIBC Private Wealth Group, LLC	6,833	$7.72K
Allworth Financial LP	1,000	$1.82K
Signaturefd, LLC	553	$769
CoreCap Advisors, LLC	290	$403
Coldstream Capital Management Inc	207	$288
Quadrant Capital Group LLC	2	$3

Not filed for Q2 2025 yet (1)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TSHA in Q1 2025 that haven't filed for Q2 2025
Institution	Shares, Q1 2025	Value, Q1 2025
Lindbrook Capital, LLC	435	$605